Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 509821, 8 pages
http://dx.doi.org/10.1155/2014/509821
Research Article

Comparison of Different Blood Collection, Sample Matrix, and Immunoassay Methods in a Prenatal Screening Setting

1Centre for Health Protection (GZB), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands
2Centre for Infectious Diseases Research, Diagnostics and Screening (IDS), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands
3Department of Obstetrics, Wilhelmina Children’s Hospital, University Medical Centre Utrecht (UMCU), P.O. Box 85090, 3508 AB Utrecht, The Netherlands

Received 26 May 2014; Accepted 4 July 2014; Published 15 July 2014

Academic Editor: Donald H. Chace

Copyright © 2014 Jeroen L. A. Pennings et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. J. Cowans, A. Stamatopoulou, J. Hellstrom, M. M. Makela, and K. Spencer, “PAPP-A and free beta-hCG stability in first trimester serum using PerkinElmer AutoDELFIA and DELFIA Xpress systems,” Prenatal Diagnosis, vol. 30, no. 2, pp. 127–132, 2010. View at Google Scholar
  2. N. J. Cowans, A. Stamatopoulou, P. Liitti, M. Suonpaa, and K. Spencer, “The stability of free-β human chorionic gonadotrophin and pregnancy-associated plasma protein-A in first trimester dried blood spots,” Prenatal Diagnosis, vol. 31, no. 3, pp. 293–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Zaragoza, R. Akolekar, L. C. Y. Poon, S. Pepes, and K. H. Nicolaides, “Maternal serum placental growth factor at 11–13 weeks in chromosomally abnormal pregnancies,” Ultrasound in Obstetrics and Gynecology, vol. 33, no. 4, pp. 382–386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Laigaard, T. Sørensen, C. Fröhlich et al., “ADAM12: a novel first-trimester maternal serum marker for Down syndrome,” Prenatal Diagnosis, vol. 23, no. 13, pp. 1086–1091, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. M. van Lith, “First-trimester maternal serum alpha-fetoprotein as a marker for fetal chromosomal disorders,” Prenatal Diagnosis, vol. 14, no. 10, pp. 963–971, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. H. Koster, E. J. Wortelboer, H. S. Cuckle, P. Stoutenbeek, G. H. A. Visser, and P. C. J. I. Schielen, “Placental protein 13 as a first trimester screening marker for aneuploidy,” Prenatal Diagnosis, vol. 29, no. 13, pp. 1237–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. M. van Lith, J. J. Pratt, J. R. Beekhuis, and A. Mantingh, “Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome,” Prenatal Diagnosis, vol. 12, no. 10, pp. 801–806, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Dugoff, J. C. Hobbins, F. D. Malone et al., “First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial),” American Journal of Obstetrics and Gynecology, vol. 191, no. 4, pp. 1446–1451, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Chafetz, I. Kuhnreich, M. Sammar et al., “First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction,” The American Journal of Obstetrics and Gynecology, vol. 197, no. 1, pp. 35.e1–35.e7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. J. Cowans, K. Spencer, and H. Meiri, “First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes,” Prenatal Diagnosis, vol. 28, no. 2, pp. 121–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kuc, E. J. Wortelboer, M. P. H. Koster, H. W. de Valk, P. C. J. I. Schielen, and G. H. A. Visser, “Prediction of macrosomia at birth in type-1 and 2 diabetic pregnancies with biomarkers of early placentation,” BJOG, vol. 118, no. 6, pp. 748–754, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. O. Odibo, K. R. Patel, A. Spitalnik, L. Odibo, and P. Huettner, “Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes,” Journal of Perinatology, vol. 34, no. 3, pp. 186–191, 2014. View at Google Scholar
  13. C. Wingren and C. A. K. Borrebaeck, “Antibody-based microarrays,” Methods in Molecular Biology, vol. 509, pp. 57–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Rodenburg, J. H. Reimerink, S. Imholz et al., “Quantitative performance of antibody array technology in a prenatal screening setting,” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 2, pp. 325–332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Ratkowsky and T. J. Reedy, “Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays,” Biometrics, vol. 42, no. 3, pp. 575–582, 1986. View at Publisher · View at Google Scholar · View at Scopus
  16. N. J. Cowans, M. Suonpaa, H. Kouru, D. Wright, and K. Spencer, “Evaluation of a dried blood spot assay to measure prenatal screening markers pregnancy-associated plasma protein A and free β-subunit of human chorionic gonadotropin,” Clinical Chemistry, vol. 59, no. 6, pp. 968–975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Krantz and J. B. Carmichael, “Impact of blood collection method on first-trimester dried blood free Beta hCG and PAPP-A,” Annals of Clinical Biochemistry, vol. 50, part 6, pp. 611–612, 2013. View at Google Scholar